Results 11 to 20 of about 14,448 (252)

Effective targeting of microglial P2X7 following intracerebroventricular delivery of nanobodies and nanobody-encoding AAVs

open access: yesFrontiers in Pharmacology, 2022
The P2X7 ion channel is a key sensor for extracellular ATP and a key trigger of sterile inflammation. Intravenous injection of nanobodies that block P2X7 has shown to be beneficial in mouse models of systemic inflammation.
Nicole Schwarz   +2 more
exaly   +3 more sources

Nanobodies as molecular imaging probes

open access: yesFree Radical Biology and Medicine, 2022
Camelidae derived single-domain antibodies (sdAbs), commonly known as nanobodies (Nbs), are the smallest antibody fragments with full antigen-binding capacity. Owing to their desirable properties such as small size, high specificity, strong affinity, excellent stability, and modularity, nanobodies are on their way to overtake conventional antibodies in
Sarah Barakat   +4 more
openaire   +5 more sources

Institute collection and analysis of Nanobodies (iCAN): a comprehensive database and analysis platform for nanobodies

open access: yesBMC Genomics, 2017
Background Nanobodies are single-domain antibodies that contain the unique structural and functional properties of naturally-occurring heavy chain in camelidae.
Jing Zuo   +9 more
doaj   +2 more sources

Characterising nanobody developability to improve therapeutic design using the Therapeutic Nanobody Profiler [PDF]

open access: yesCommunications Biology
Developability optimisation is an important step for successful biotherapeutic design. For monoclonal antibodies, developability is relatively well characterised. However, progress for novel biotherapeutics such as nanobodies is more limited. Differences
Gemma L. Gordon   +3 more
doaj   +2 more sources

Camelid-Derived Nanobodies Targeting Human Epidermal Growth Factor Receptor: Screening, Expression, and Functional Validation [PDF]

open access: yesAntibodies
Objectives: The epidermal growth factor receptor (EGFR) is a clinically relevant membrane receptor that is frequently overexpressed or dysregulated in multiple types of cancer, making it an important target for antibody-based strategies.
Yunfeng Liu   +7 more
doaj   +2 more sources

Applications of nanobodies in brain diseases

open access: yesFrontiers in Immunology, 2022
Nanobodies are antibody fragments derived from camelids, naturally endowed with properties like low molecular weight, high affinity and low immunogenicity, which contribute to their effective use as research tools, but also as diagnostic and therapeutic ...
Fang Zheng   +7 more
doaj   +4 more sources

Cell-Based Immunization Combined with Single-Round Cell Panning Enables Discovery of PSMA-Targeting Nanobodies from Phage Display Libraries [PDF]

open access: yesBiomolecules
There is a strong need for nanobodies that target novel cancer-associated antigens to advance radioligand imaging and antibody-based therapeutics. In this study, we investigated whether non-targeted llama immunization using tumor cells, combined with non-
Tong Yang   +17 more
doaj   +2 more sources

Nanobodies—Useful Tools for Allergy Treatment?

open access: yesFrontiers in Immunology, 2020
In the last decade single domain antibodies (nanobodies, VHH) qualified through their unique characteristics have emerged as accepted and even advantageous alternative to conventional antibodies and have shown great potential as diagnostic and ...
Sabine Flicker   +2 more
doaj   +2 more sources

Nanobodies: From Discovery to AI-Driven Design

open access: yesBiology
Nanobodies, derived from naturally occurring heavy-chain antibodies in camelids (VHHs) and sharks (VNARs), are unique single-domain antibodies that have garnered significant attention in therapeutic, diagnostic, and biotechnological applications due to ...
Haoran Zhu, Yu Ding
doaj   +2 more sources

Structure of Nanobody Nb23 [PDF]

open access: yesMolecules, 2021
Background: Nanobodies, or VHHs, are derived from heavy chain-only antibodies (hcAbs) found in camelids. They overcome some of the inherent limitations of monoclonal antibodies (mAbs) and derivatives thereof, due to their smaller molecular size and higher stability, and thus present an alternative to mAbs for therapeutic use.
Percipalle M.   +4 more
openaire   +5 more sources

Home - About - Disclaimer - Privacy